Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways.
Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, Oksanen LJ, Thornton-Jones ZD, Clifton PG, Yueh CY, Evans ML, McCrimmon RJ, Elmquist JK, Butler AA, Heisler LK.
Cell Metab. 2007 Nov;6(5):398-405.PMID: 17983585 [PubMed - indexed for MEDLINE]Related articlesFree article